AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 414344 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 414344 — intervention group
Group type: EXPERIMENTAL
Intervention: Floctafenine 1.6 g daily for 3-6 months
Number of subjects: 48
Study 29298622 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ10 (400 mg/day)
Number of subjects: 45
Study 29298622 — intervention group
Group type: COMPARATOR
Intervention: Placebo (wheat starch)
Number of subjects: 45
Study 28879245 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% capsaicin cream
Number of subjects: 0
Study 28879245 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 0
Study 26237980 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal medicine + auricular pressure (treatment group)
Number of subjects: 66
Study 26237980 — intervention group
Group type: COMPARATOR
Intervention: Chinese herbal medicine (control group)
Number of subjects: 66
Study 26237980 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (treatment and control)
Number of subjects: 66
Study 26237980 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 66
Study 26237980 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group
Number of subjects: 66
Study 24139639 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral pre-exposure prophylaxis (PrEP) for HIV prevention
Number of subjects: 3163
Study 21504351 — intervention group
Group type: EXPERIMENTAL
Intervention: Talking to friends about asthma
Number of subjects: 835
Study 21504351 — intervention group
Group type: EXPERIMENTAL
Intervention: Worry, concern, or trouble about asthma
Number of subjects: 835
Study 21504351 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional quality of life
Number of subjects: 835
Study 19706240 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (selective COX-2 inhibitor) for 1 week
Number of subjects: 40
Study 19706240 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 40
Study 16773176 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin prick test for B. germanica
Number of subjects: 118
Study 16773176 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin prick test for P. americana
Number of subjects: 118
Study 16773176 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific IgE for B. germanica
Number of subjects: 118
Study 16773176 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific IgE for P. americana
Number of subjects: 118
Study 16773176 — intervention group
Group type: EXPERIMENTAL
Intervention: Total IgE levels
Number of subjects: 118
Study 16773176 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin prick test and specific IgE correlation
Number of subjects: 118
Study 16773176 — intervention group
Group type: EXPERIMENTAL
Intervention: Cockroach-specific IgE
Number of subjects: 118
Study 15313938 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease Management (DM) for 90 days
Number of subjects: 200
Study 15313938 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 200
Study 10717011 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (0.4 mg/kg subcutaneously twice weekly for up to three months)
Number of subjects: 69
Study 10717011 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (in double-blind study)
Number of subjects: 69
Study 10717011 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in double-blind study)
Number of subjects: 69
Study 10717011 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 10717011 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 69
Study 10717011 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept and Placebo
Number of subjects: 69
Study 9113213 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol rehabilitation program treatment
Number of subjects: 74
Study 9113213 — intervention group
Group type: COMPARATOR
Intervention: Comparison group for practice effects
Number of subjects: 74
Study 8111484 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine and mazindol (combined)
Number of subjects: 1163
Study 8111484 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1163
Study 8111484 — intervention group
Group type: EXPERIMENTAL
Intervention: Mazindol
Number of subjects: 1163
Study 2870226 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS 201-995, 50 micrograms/h, continuous intravenous infusion
Number of subjects: 10
Study 2975549 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 35
Study 2975549 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 35
Study 2975549 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide and Metformin
Number of subjects: 35
Study 31454829 — intervention group
Group type: EXPERIMENTAL
Intervention: AKI risk alerts intervention
Number of subjects: 3006
Study 31454829 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3006
Study 31021944 — intervention group
Group type: EXPERIMENTAL
Intervention: McNamara education program (experimental group)
Number of subjects: 70
Study 31021944 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 70
Study 28475456 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral brigatinib 90 mg once daily (arm A)
Number of subjects: 222
Study 28475456 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral brigatinib 180 mg once daily with a 7-day lead-in at 90 mg (arm B)
Number of subjects: 222
Study 26145274 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxes on low nutrient dense foods (e.g. sweetened beverages, candy, salty snacks)
Number of subjects: 199
Study 26145274 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsidies on fruits, vegetables, and bottled water (12.5% or 25%)
Number of subjects: 199
Study 26145274 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxes on grains
Number of subjects: 199
Study 26145274 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsidies on grains
Number of subjects: 199
Study 26145274 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsidies on miscellaneous foods
Number of subjects: 199
Study 26145274 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsidies on foods purchased
Number of subjects: 199
Study 23276359 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid constructs (artificial disk replacement combined with midlevel ACDF)
Number of subjects: 24
Study 23276359 — intervention group
Group type: COMPARATOR
Intervention: 3-level ACDF
Number of subjects: 24
Study 21477037 — intervention group
Group type: EXPERIMENTAL
Intervention: Quartz-tungsten-halogen (QTH) - 450 mW/cm²
Number of subjects: 50
Study 21477037 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser (LAS) - 300 mW/cm²
Number of subjects: 50
Study 21477037 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation light-emitting diode (LED 2) - 1100 mW/cm²
Number of subjects: 50
Study 21477037 — intervention group
Group type: EXPERIMENTAL
Intervention: Third generation LED - 700 mW/cm²
Number of subjects: 50
Study 21477037 — intervention group
Group type: EXPERIMENTAL
Intervention: Whisky
Number of subjects: 50
Study 21477037 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine
Number of subjects: 50
Study 21477037 — intervention group
Group type: EXPERIMENTAL
Intervention: Distilled water
Number of subjects: 50
Study 21477037 — intervention group
Group type: COMPARATOR
Intervention: Cola
Number of subjects: 50
Study 21477037 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee
Number of subjects: 50
Study 18679669 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebicapone 200 mg thrice daily for 9 days with racemic warfarin 25 mg single dose on day 4
Number of subjects: 16
Study 18679669 — intervention group
Group type: COMPARATOR
Intervention: Racemic warfarin 25 mg single dose alone
Number of subjects: 16
Study 18679669 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebicapone
Number of subjects: 16
Study 16434127 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS02A
Number of subjects: 18
Study 16434127 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA-CS
Number of subjects: 18
Study 16434127 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterologous prime-boost (RTS,S followed by MVA-CS)
Number of subjects: 18
Study 16434127 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterologous prime-boost (MVA-CS followed by RTS,S)
Number of subjects: 18
Study 14646973 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive anticardiolipin antibody (ACLA) levels in adolescents in the case group (parents with MI<55 years)
Number of subjects: 150
Study 14646973 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive anticardiolipin antibody (ACLA) levels in parents of adolescents in the case group (parents with MI<55 years)
Number of subjects: 150
Study 14646973 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of positive ACLA between parents with premature MI and their children
Number of subjects: 150
Study 10715297 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin/Heparin/Ciprofloxacin flush solution (VHC)
Number of subjects: 126
Study 10715297 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin/Heparin (VH)
Number of subjects: 126
Study 10715297 — intervention group
Group type: COMPARATOR
Intervention: Heparin alone
Number of subjects: 126
Study 9361168 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg once daily
Number of subjects: 509
Study 9361168 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 10 mg once daily
Number of subjects: 509
Study 9361168 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 509
Study 1546824 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser skin testing
Number of subjects: 20
Study 1546824 — intervention group
Group type: COMPARATOR
Intervention: Puncture testing with Morrow‐Brown Needle
Number of subjects: 20
Study 3982273 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (400 mg added to decaffeinated coffee)
Number of subjects: 9
Study 3982273 — intervention group
Group type: COMPARATOR
Intervention: Decaffeinated coffee (control)
Number of subjects: 9
Study 29623447 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted lopinavir (LPV/r) based antiretroviral therapy (ART)
Number of subjects: 219
Study 29623447 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz-based ART
Number of subjects: 219
Study 29623447 — intervention group
Group type: COMPARATOR
Intervention: HIV-infected children (both ART groups)
Number of subjects: 219
Study 29623447 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected children on LPV/r
Number of subjects: 219
Study 27029920 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (vancomycin or daptomycin)
Number of subjects: 440
Study 27029920 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard therapy plus 7 days of an anti‐staphylococcal β‐lactam (flucloxacillin, cloxacillin, or cefazolin)
Number of subjects: 440
Study 24496567 — intervention group
Group type: EXPERIMENTAL
Intervention: SL-OCT imaging
Number of subjects: 40
Study 22959512 — intervention group
Group type: EXPERIMENTAL
Intervention: Grouping of two rams in a neutral pen
Number of subjects: 12
Study 20351334 — intervention group
Group type: EXPERIMENTAL
Intervention: vinflunine 320 mg/m² every 21 days
Number of subjects: 551
Study 20351334 — intervention group
Group type: COMPARATOR
Intervention: docetaxel 75 mg/m² every 21 days
Number of subjects: 551
Study 18261667 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonography
Number of subjects: 29
Study 18261667 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve conduction study (NCS)
Number of subjects: 29
Study 18261667 — intervention group
Group type: COMPARATOR
Intervention: Comparison of sonography and NCS
Number of subjects: 29
Study 18261667 — intervention group
Group type: COMPARATOR
Intervention: Cross-sectional area (CSA) measurement
Number of subjects: 29
Study 17273677 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital retinographer injecting 2 ml fluorescein at 10%
Number of subjects: 70
Study 17273677 — intervention group
Group type: COMPARATOR
Intervention: Conventional retinographer injecting 5 ml sodium fluorescein at 10%
Number of subjects: 70
Study 17273677 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (control and study)
Number of subjects: 70
Study 11896774 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical vitamin C preparation (10% ascorbic acid and 7% tetrahexyldecyl ascorbate in polysilicone gel)
Number of subjects: 10
Study 11896774 — intervention group
Group type: COMPARATOR
Intervention: Inactive polysilicone gel base (control)
Number of subjects: 10
Study 10776116 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational materials, counseling, special evening clinics, reminders of scheduled Pap appointments
Number of subjects: 481
Study 10776116 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 481
Study 7824129 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI criteria for MS
Number of subjects: 36
Study 2362094 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic beta-carotene supplementation
Number of subjects: 12
Study 2362094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6777178 — intervention group
Group type: EXPERIMENTAL
Intervention: Procainamide
Number of subjects: 10
Study 6777178 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocainide
Number of subjects: 10
Study 6777178 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocainide 400 mg every 8 h
Number of subjects: 10
Study 6777178 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocainide (after 6 months treatment)
Number of subjects: 10
Study 29925316 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol anesthesia
Number of subjects: 36
Study 29925316 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane anesthesia
Number of subjects: 36
Study 29925316 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 36
Study 27026059 — intervention group
Group type: EXPERIMENTAL
Intervention: Avocado-soybean unsaponifiable extract (ASU)
Number of subjects: 14
Study 27026059 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 24356474 — intervention group
Group type: EXPERIMENTAL
Intervention: ETN + MTX
Number of subjects: 423
Study 24356474 — intervention group
Group type: COMPARATOR
Intervention: DMARD + MTX
Number of subjects: 423
Study 21492237 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant treatment in patients with OLP
Number of subjects: 36
Study 21492237 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-OLP patients)
Number of subjects: 36
Study 20497755 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (TNF-alpha receptor antagonist), administered twice weekly for 44 weeks
Number of subjects: 10
Study 20497755 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 17362422 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcelain inlays cemented with dental adhesive and composite resin cement
Number of subjects: 32
Study 17362422 — intervention group
Group type: COMPARATOR
Intervention: Control group (no restorations)
Number of subjects: 32
Study 15751771 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone 4 mg, twice daily
Number of subjects: 64
Study 15751771 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 64
Study 12192016 — intervention group
Group type: EXPERIMENTAL
Intervention: Total mastectomy with radiation
Number of subjects: 1665
Study 12192016 — intervention group
Group type: EXPERIMENTAL
Intervention: Total mastectomy without radiation
Number of subjects: 1665
Study 12192016 — intervention group
Group type: EXPERIMENTAL
Intervention: Total mastectomy with radiation (positive nodes)
Number of subjects: 1665
Study 12192016 — intervention group
Group type: COMPARATOR
Intervention: Radical mastectomy
Number of subjects: 1665
Study 9571600 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous estradiol (pE2) 1.5 mg/day
Number of subjects: 43
Study 9571600 — intervention group
Group type: COMPARATOR
Intervention: Oral estriol (E3) 2 mg/day
Number of subjects: 43
Study 9571600 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous estradiol (pE2) 1.5 mg/day (3rd year follow-up)
Number of subjects: 43
Study 7803550 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 25 mg
Number of subjects: 20
Study 7803550 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2846947 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 299
Study 2846947 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 299
Study 2846947 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepindolol
Number of subjects: 299
Study 2846947 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 299
Study 28847792 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone pulse therapy
Number of subjects: 0
Study 28847792 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 28735847 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TENS
Number of subjects: 37
Study 28735847 — intervention group
Group type: COMPARATOR
Intervention: Placebo TENS
Number of subjects: 37
Study 25836006 — intervention group
Group type: EXPERIMENTAL
Intervention: Microimplant anchorage
Number of subjects: 31
Study 25836006 — intervention group
Group type: COMPARATOR
Intervention: Headgear anchorage
Number of subjects: 31
Study 24579474 — intervention group
Group type: EXPERIMENTAL
Intervention: BIFICO therapy for 4 consecutive days
Number of subjects: 490
Study 24579474 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 490
Study 21689897 — intervention group
Group type: EXPERIMENTAL
Intervention: Group drug counseling
Number of subjects: 438
Study 20078008 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased total sleep time (TST)
Number of subjects: 90
Study 20078008 — intervention group
Group type: EXPERIMENTAL
Intervention: Fewer respiratory awakenings
Number of subjects: 90
Study 20078008 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher oxygen saturation (SaO(2)) nadir
Number of subjects: 90
Study 20078008 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased TST
Number of subjects: 90
Study 17027149 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) training for 5 weeks, consisting of 15 sessions of isometric NMES.
Number of subjects: 19
Study 17027149 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) training for 5 weeks.
Number of subjects: 19
Study 14559889 — intervention group
Group type: COMPARATOR
Intervention: Government-sponsored trial
Number of subjects: 20
Study 14559889 — intervention group
Group type: COMPARATOR
Intervention: Pharmaceutical industry-sponsored trial
Number of subjects: 20
Study 14559889 — intervention group
Group type: COMPARATOR
Intervention: Industry-sponsored trial
Number of subjects: 20
Study 14559889 — intervention group
Group type: COMPARATOR
Intervention: Nonclinical activities
Number of subjects: 20
Study 11127853 — intervention group
Group type: EXPERIMENTAL
Intervention: STA Liatest D‐dimer
Number of subjects: 123
Study 11127853 — intervention group
Group type: EXPERIMENTAL
Intervention: MDA D‐dimer
Number of subjects: 123
Study 11127853 — intervention group
Group type: COMPARATOR
Intervention: VIDAS D‐dimer (reference method)
Number of subjects: 123
Study 9344305 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory sensory feedback during treadmill walking at speeds of 1, 2, and 2.5 mph.
Number of subjects: 50
Study 7981178 — intervention group
Group type: EXPERIMENTAL
Intervention: lovastatin 40 mg twice daily
Number of subjects: 63
Study 7981178 — intervention group
Group type: COMPARATOR
Intervention: matching placebo tablets twice daily
Number of subjects: 63
Study 2725184 — intervention group
Group type: COMPARATOR
Intervention: 10 ug/kg atropine intravenously
Number of subjects: 50
Study 2725184 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ug/kg atropine endotracheally
Number of subjects: 50
Study 2725184 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ug/kg atropine endotracheally
Number of subjects: 50
Study 2725184 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 ug/kg atropine endotracheally
Number of subjects: 50
Study 2725184 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 ug/kg atropine endotracheally
Number of subjects: 50
Study 4570671 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (120 mg thrice daily)
Number of subjects: 32
Study 4570671 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (100 mg thrice daily)
Number of subjects: 32
Study 4570671 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (20 mg thrice daily)
Number of subjects: 32
Study 4570671 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 30219958 — intervention group
Group type: EXPERIMENTAL
Intervention: Other-focus perspective setting
Number of subjects: 2
Study 30219958 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-focus perspective setting
Number of subjects: 2
Study 30219958 — intervention group
Group type: COMPARATOR
Intervention: Baseline perspective setting
Number of subjects: 2
Study 28267354 — intervention group
Group type: EXPERIMENTAL
Intervention: Body size-specific organ and effective doses calculated using the National Cancer Institute CT (NCICT) dosimetry program.
Number of subjects: 23734
Study 28267354 — intervention group
Group type: COMPARATOR
Intervention: Reference phantom-based dose calculation.
Number of subjects: 23734
Study 28267354 — intervention group
Group type: EXPERIMENTAL
Intervention: Effective dose calculations for body size-specific groups.
Number of subjects: 23734
Study 25344736 — intervention group
Group type: EXPERIMENTAL
Intervention: Work-based mentoring programme (150 hours of mentored clinical practice)
Number of subjects: 720
Study 25344736 — intervention group
Group type: COMPARATOR
Intervention: Usual in-service training
Number of subjects: 720
Study 22455972 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation (PMR) training for 12 weeks
Number of subjects: 100
Study 22455972 — intervention group
Group type: COMPARATOR
Intervention: Depot leuprolide, 11.25mg IM (both groups)
Number of subjects: 100